X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Orchid Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ORCHID PHARMA LTD - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ORCHID PHARMA LTD NOVARTIS/
ORCHID PHARMA LTD
 
P/E (TTM) x 347.8 -0.8 - View Chart
P/BV x 17.1 0.6 3,065.1% View Chart
Dividend Yield % 1.7 0.0 -  

Financials

 NOVARTIS   ORCHID PHARMA LTD
EQUITY SHARE DATA
    NOVARTIS
Mar-16
ORCHID PHARMA LTD
Sep-13
NOVARTIS/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs982194 506.2%   
Low Rs55635 1,589.1%   
Sales per share (Unadj.) Rs252.9276.5 91.5%  
Earnings per share (Unadj.) Rs62.1-79.2 -78.5%  
Cash flow per share (Unadj.) Rs63.3-43.5 -145.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs363.653.9 674.2%  
Shares outstanding (eoy) m31.9670.45 45.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.00.4 734.2%   
Avg P/E ratio x12.4-1.4 -856.2%  
P/CF ratio (eoy) x12.2-2.6 -461.1%  
Price / Book Value ratio x2.12.1 99.6%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m24,5808,067 304.7%   
No. of employees `0000.82.8 26.9%   
Total wages/salary Rs m1,8012,527 71.3%   
Avg. sales/employee Rs Th10,748.96,956.1 154.5%   
Avg. wages/employee Rs Th2,395.2902.5 265.4%   
Avg. net profit/employee Rs Th2,641.1-1,993.0 -132.5%   
INCOME DATA
Net Sales Rs m8,08319,477 41.5%  
Other income Rs m829407 203.7%   
Total revenues Rs m8,91319,884 44.8%   
Gross profit Rs m2341,103 21.2%  
Depreciation Rs m372,519 1.5%   
Interest Rs m25,227 0.0%   
Profit before tax Rs m1,025-6,236 -16.4%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,696511 332.0%   
Tax Rs m752-125 -600.6%   
Profit after tax Rs m1,986-5,580 -35.6%  
Gross profit margin %2.95.7 51.2%  
Effective tax rate %73.42.0 3,654.0%   
Net profit margin %24.6-28.7 -85.8%  
BALANCE SHEET DATA
Current assets Rs m12,67811,014 115.1%   
Current liabilities Rs m2,43332,060 7.6%   
Net working cap to sales %126.7-108.1 -117.3%  
Current ratio x5.20.3 1,516.8%  
Inventory Days Days3395 34.5%  
Debtors Days Days2234 67.0%  
Net fixed assets Rs m6929,440 0.2%   
Share capital Rs m160705 22.7%   
"Free" reserves Rs m11,4602,043 561.0%   
Net worth Rs m11,6213,800 305.8%   
Long term debt Rs m09,018 0.0%   
Total assets Rs m14,40046,510 31.0%  
Interest coverage x570.5-0.2 -295,412.1%   
Debt to equity ratio x02.4 0.0%  
Sales to assets ratio x0.60.4 134.0%   
Return on assets %13.8-0.8 -1,816.4%  
Return on equity %17.1-146.9 -11.6%  
Return on capital %23.6-3.7 -631.3%  
Exports to sales %0.737.9 2.0%   
Imports to sales %18.622.6 82.2%   
Exports (fob) Rs m607,378 0.8%   
Imports (cif) Rs m1,5034,406 34.1%   
Fx inflow Rs m1867,513 2.5%   
Fx outflow Rs m1,8215,649 32.2%   
Net fx Rs m-1,6351,865 -87.7%   
CASH FLOW
From Operations Rs m2,5311,682 150.5%  
From Investments Rs m-8,270-9,860 83.9%  
From Financial Activity Rs m-3866,644 -5.8%  
Net Cashflow Rs m-6,125-1,535 399.0%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 4.6 43.5%  
FIIs % 1.6 3.3 48.5%  
ADR/GDR % 0.0 4.6 -  
Free float % 21.5 55.3 38.9%  
Shareholders   41,647 84,811 49.1%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   DISHMAN PHARMA  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 18, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - SANOFI INDIA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS